Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects With Type 2 Diabetes and Nephropathy SONAR: Study Of Diabetic Nephropathy With Atrasentan

Trial Profile

A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects With Type 2 Diabetes and Nephropathy SONAR: Study Of Diabetic Nephropathy With Atrasentan

Discontinued
Phase of Trial: Phase III

Latest Information Update: 25 Apr 2019

At a glance

  • Drugs Atrasentan (Primary)
  • Indications Diabetic nephropathies
  • Focus Registrational; Therapeutic Use
  • Acronyms SONAR
  • Sponsors AbbVie
  • Most Recent Events

    • 15 Apr 2019 Results published in the Lancet
    • 24 Apr 2018 Status changed from active, no longer recruiting to discontinued.
    • 18 Apr 2018 This trial has been discontinued in Austria.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top